Analytical Data
-
Gene name
p85/p110
- Application
-
Alternative Names
GRB1
-
Species
Human
-
Source
Baculovirus
-
Tag
Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P27986-1 (A318-D615)&P42336
-
Expression Region
P27986-1 (A318-D615)&P42336 (P2-N1068, P539R)
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The P85/P110 complex, composed of the regulatory subunit P85 and the catalytic subunit P110 of phosphoinositide 3-kinase (PI3K), plays a critical role in cellular signaling pathways that regulate various cellular functions, including growth, proliferation, and metabolism. Research into P85/P110 has gained prominence due to its involvement in cancer progression and other diseases, where aberrant PI3K signaling is often implicated. The PI3K pathway is activated by various growth factors and hormones, leading to the production of phosphatidylinositol-(3,4,5)-trisphosphate (PIP3), which serves as a secondary messenger to activate downstream signaling proteins such as AKT. Dysregulation of this pathway can lead to uncontrolled cell division and survival, highlighting its significance as a therapeutic target. Understanding the structural and functional dynamics of P85/P110 not only illuminates the mechanistic underpinnings of PI3K-related diseases but also paves the way for the development of specific inhibitors that could be used in clinical settings. Recent studies have focused on the detailed characterization of P85/P110 interactions, their regulatory mechanisms, and the impact of various mutations associated with cancer, providing insights that are crucial for designing targeted therapies aimed at modulating this pathway. As a result, the P85/P110 complex remains a vital subject of investigation within cancer biology and drug development, with the potential to contribute to more effective treatment strategies against malignancies driven by PI3K pathway alterations.
